EUVIMEDEUVIMED entdecken
Vergleichsstudie

Rome III Versus Rome IV Criteria for Diagnosing Irritable Bowel Syndrome in a Southeast Asian Population: Insights From the Rome Foundation Global Epidemiology Study Household Survey

Daniel Martin Simadibrata iD, Thai Hau Koo iD, Amanda Pitarini Utari, Mina Ayad, Kueh Yee Cheng, Ami D Sperber, Bangdiwala Shrikant, Olafur S Palsson, Ari Fahrial Syam, Yeong Yeh Lee iD

Journal of Gastroenterology and Hepatology · 2026

DOI: 10.1111/jgh.70174 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2026. Verfasst von Daniel Martin Simadibrata und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Ironwood Pharmaceuticals, Incorporated, Ironwood Pharmaceuticals Inc., Ministry of Education of Malaysia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Previous Asian studies have reported a substantial decline in irritable bowel syndrome (IBS) prevalence following the adoption of the Rome IV diagnostic criteria. However, comparative data on IBS prevalence using Rome III and Rome IV criteria remain sparse, especially in Southeast Asia.

Methods

We analyzed household survey data from the Rome Foundation Global Epidemiology Study conducted in Malaysia and Indonesia, the only Southeast Asian countries included in the study, utilizing household‐based sampling. We compared diagnostic sensitivity between Rome III and Rome IV criteria for IBS and examined demographic characteristics, symptom severity, psychological distress, quality of life (QoL), healthcare utilization, and dietary habits among identified IBS participants.

Result

Of 3411 participants (Malaysia: 2072; Indonesia: 1339), 177 (5.2%) fulfilled IBS criteria according to either Rome III or IV criteria. Among these, 115 (65%) met only the Rome III criteria, 50 (28%) met both the Rome III and IV criteria, and 12 (7%) exclusively met the Rome IV criteria. Compared with those diagnosed by Rome III, individuals identified by Rome IV criteria were younger and predominantly female. Only 31% of the Rome III IBS cases remained classified as IBS under the Rome IV criteria, while others were reclassified as unspecified bowel disorder (24%) or functional constipation (17%). While healthcare utilization rates were similar across groups, Rome IV IBS participants exhibited significantly higher symptom severity, lower anxiety levels, and poorer mental health‐related QoL. Dietary assessments revealed significantly lower intake of milk, meat products, fish, eggs, vegetables and legumes, fruit, bread, and pasta among Rome IV IBS participants.

Conclusion

The Rome IV criteria for IBS demonstrate reduced diagnostic sensitivity compared with the Rome III criteria in the Southeast Asian populations. Individuals meeting the Rome IV criteria displayed distinct demographic and clinical characteristics, including greater symptom severity and reduced mental health‐related QoL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Irritable Bowel SyndromeHumansFemaleMaleAdultMiddle AgedQuality of LifePrevalenceMalaysiaSeverity of Illness IndexIndonesiaYoung AdultSurveys and QuestionnairesAgedAdolescentSoutheast Asian People

Stichwörter der Autor:innen

IndonesiaMalaysiaRome criteriahealthcare utilizationirritable bowel syndromepsychosocial disturbance

Autor:innen und Institutionen

  • Department of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
  • Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
  • School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia.
  • Gastrointestinal Function and Motility Unit, Hospital USM, Kota Bharu, Malaysia.
  • Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
  • Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

ORCID-Profile: Daniel Martin Simadibrata, Thai Hau Koo, Yeong Yeh Lee

Förderung

  • Ironwood Pharmaceuticals, Incorporated
  • Ironwood Pharmaceuticals Inc.
  • Ministry of Education of Malaysia
  • Shire
  • Allergan
  • Takeda Medical Research Foundation
  • Rome Foundation

Zitieren

APA

Simadibrata, D. M., Koo, T. H., Utari, A. P., Ayad, M., Cheng, K. Y., Sperber, A. D., Shrikant, B., Palsson, O. S., Syam, A. F., & Lee, Y. Y. (2026). Rome III Versus Rome IV Criteria for Diagnosing Irritable Bowel Syndrome in a Southeast Asian Population: Insights From the Rome Foundation Global Epidemiology Study Household Survey. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70174

Vancouver

Simadibrata DM, Koo TH, Utari AP, Ayad M, Cheng KY, Sperber AD, et al. Rome III Versus Rome IV Criteria for Diagnosing Irritable Bowel Syndrome in a Southeast Asian Population: Insights From the Rome Foundation Global Epidemiology Study Household Survey. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70174

BibTeX
@article{Simadibrata2026,
  author = {Simadibrata, Daniel Martin and Koo, Thai Hau and Utari, Amanda Pitarini and Ayad, Mina and Cheng, Kueh Yee and Sperber, Ami D and Shrikant, Bangdiwala and Palsson, Olafur S and Syam, Ari Fahrial and Lee, Yeong Yeh},
  title = {Rome III Versus Rome IV Criteria for Diagnosing Irritable Bowel Syndrome in a Southeast Asian Population: Insights From the Rome Foundation Global Epidemiology Study Household Survey},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  doi = {10.1111/jgh.70174}
}
Kostenlos starten →